Scholar aims to reverse-engineer cancer with 3D tool

by Kim Horner,University of Texas at DallasDr. Chen Cao (center), assistant professor of bioengineering, is shown with some members of her lab, from left, biomedical engineering junior Namyuktha

Updated on: September 28,2024

Scholar aims to reverse-engineer cancer with 3D tool

by Kim Horner,University of Texas at DallasDr. Chen Cao (center), assistant professor of bioengineering, is shown with some members of her lab, from left, biomedical engineering junior Namyuktha

Updated on:September 28,2024

New gene implicated in cancer, cellular stress response

by Olivia Dimmer,Northwestern UniversityTissue-restricted expression of mammalian HAPSTR2. a Transcript abundance of HAPSTR1 and HAPSTR2 in the indicated human tissues; GTEx RNA-seq data. TPM, t

Updated on: February 18,2024

New gene implicated in cancer, cellular stress response

by Olivia Dimmer,Northwestern UniversityTissue-restricted expression of mammalian HAPSTR2. a Transcript abundance of HAPSTR1 and HAPSTR2 in the indicated human tissues; GTEx RNA-seq data. TPM, t

Updated on:February 18,2024

Researchers create a cell therapy based on STAb cells for a type of leukemia with few treatment options

by Josep Carreras Leukaemia Research InstituteComparative in vitro study of engineered CD1a-STAb and CD1a-CAR T cells. (A, B) Schematic diagrams showing the genetic (A) and domain structure (B) o

Updated on: February 18,2024

Researchers create a cell therapy based on STAb cells for a type of leukemia with few treatment options

by Josep Carreras Leukaemia Research InstituteComparative in vitro study of engineered CD1a-STAb and CD1a-CAR T cells. (A, B) Schematic diagrams showing the genetic (A) and domain structure (B) o

Updated on:February 18,2024

Drug combo slows progression in advanced breast cancer

(HealthDay)—Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients withPIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth

Updated on: May 23,2024

Drug combo slows progression in advanced breast cancer

(HealthDay)—Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients withPIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth

Updated on:May 23,2024

Researchers design 'prodrug' that targets cancer cells' big appetite for glutamine, leaving healthy cells unharmed

by Johns Hopkins University School of MedicineSchematic showing DRP-104's bio-activation to DON in tumor and bio-inactivation to an inert metabolite in GI tissues. Credit: Jennifer E. Fairman

Updated on: February 18,2024

Researchers design 'prodrug' that targets cancer cells' big appetite for glutamine, leaving healthy cells unharmed

by Johns Hopkins University School of MedicineSchematic showing DRP-104's bio-activation to DON in tumor and bio-inactivation to an inert metabolite in GI tissues. Credit: Jennifer E. Fairman

Updated on:February 18,2024

Researchers invent novel ingestible capsule X-ray dosimeter for real-time radiotherapy monitoring

by National University of SingaporeThe components of the dosimeter fit into an 18mm by 7mm capsule, a common size for many supplements and medicines. Credit: National University of SingaporeGastr

Updated on: February 23,2024

Researchers invent novel ingestible capsule X-ray dosimeter for real-time radiotherapy monitoring

by National University of SingaporeThe components of the dosimeter fit into an 18mm by 7mm capsule, a common size for many supplements and medicines. Credit: National University of SingaporeGastr

Updated on:February 23,2024

Researchers program cancer-fighting cells to resist exhaustion, attack solid tumors in mice

by Stanford University Medical CenterCredit: CC0 Public DomainA new approach to programing cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiven

Updated on: June 24,2024

Researchers program cancer-fighting cells to resist exhaustion, attack solid tumors in mice

by Stanford University Medical CenterCredit: CC0 Public DomainA new approach to programing cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiven

Updated on:June 24,2024

Study identifies how cancer-causing gene regulates genetic variation in prostate cancer

by Queen Mary, University of LondonGraphical abstract. Credit:Cell Reports(2022). DOI: 10.1016/j.celrep.2022.111404Researchers from Barts Cancer Institute (BCI) at Queen Mary Universi

Updated on: January 30,2024

Study identifies how cancer-causing gene regulates genetic variation in prostate cancer

by Queen Mary, University of LondonGraphical abstract. Credit:Cell Reports(2022). DOI: 10.1016/j.celrep.2022.111404Researchers from Barts Cancer Institute (BCI) at Queen Mary Universi

Updated on:January 30,2024

EU approves treatment for prostate cancer

Prostate cancer cells. Credit: NIH Image GalleryThe European Union has approved a new treatment against an advanced type of prostate cancer by Novartis, the Swiss pharmaceutical giant said Tuesday.The

Updated on: January 02,2024

EU approves treatment for prostate cancer

Prostate cancer cells. Credit: NIH Image GalleryThe European Union has approved a new treatment against an advanced type of prostate cancer by Novartis, the Swiss pharmaceutical giant said Tuesday.The

Updated on:January 02,2024

Genes activated in metastasis also drive the first stages of tumour growth

by Institute for Research in Biomedicine (IRB Barcelona)The overexpression of the gene Serpent in the Drosophila wing causes permanent overgrowth and it is sufficient to promote tumour developmen

Updated on: March 01,2024

Genes activated in metastasis also drive the first stages of tumour growth

by Institute for Research in Biomedicine (IRB Barcelona)The overexpression of the gene Serpent in the Drosophila wing causes permanent overgrowth and it is sufficient to promote tumour developmen

Updated on:March 01,2024

First randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

by ECOG-ACRIN Cancer Research GroupCredit: Pixabay/CC0 Public DomainThe ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of

Updated on: January 04,2024

First randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer

by ECOG-ACRIN Cancer Research GroupCredit: Pixabay/CC0 Public DomainThe ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of

Updated on:January 04,2024

Inhibitor shows lasting structural integrity and long terminal half-life in tumor tissue

by Vall d'Hebron Institute of OncologyLaura Soucek, co-Director of Preclinical and Translational Research at VHIO, Chief Executive Officer of Peptomyc, and an ICREA Research Professor. Credit: VHI

Updated on: February 18,2024

Inhibitor shows lasting structural integrity and long terminal half-life in tumor tissue

by Vall d'Hebron Institute of OncologyLaura Soucek, co-Director of Preclinical and Translational Research at VHIO, Chief Executive Officer of Peptomyc, and an ICREA Research Professor. Credit: VHI

Updated on:February 18,2024